Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

Deaths among hospitalized patients with bladder cancer in the United States significantly increased from 4.5% in 2008 to 4.9% in 2021, driven by increased mortality among specific subgroups, ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.62, expectations were $-0.7. Operator: Greetings, and welcome to the Relmada ...

The news from Buckingham palace was shocking. Over a year after King Charles had announced that he had been diagnosed with ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive ...

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in ...